Ovarian cancer at young age: the contribution of mismatch-repair defects in a population-based series of epithelial ovarian cancer before age 40.
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Introduction
Ovarian cancer is a major cause of death from gynecologic cancer and heredity is estimated to cause at least 10% of the cases (1, 2) . Although ovarian cancer has most commonly been associated with hereditary breast and ovarian cancer due to mutations in the BRCA-genes, ovarian cancer also occurs within the hereditary nonpolyposis colorectal cancer (HNPCC) syndrome, and as site specific ovarian cancer with a yet unknown genetic background (2, 3) .
Characterization of familial predisposition to ovarian cancer and the underlying genetic causes hereof is important since risks may apply also for other tumor types e.g. breast cancer, colorectal cancer, and endometrial cancer for which preventive measures may be beneficial.
Although control programmes have not proven effective for ovarian cancer, prophylactic salpingo-oophorectomy effectively reduces cancer risk in women with a hereditary predisposition for ovarian cancer (4) (5) (6) . HNPCC, or Lynch syndrome, is an autosomal dominant cancer syndrome in which mutation carriers have increased life-time risks of several cancer types, with the highest risks for colorectal cancer (80%), endometrial cancer (40-60%), and ovarian cancer (12%) (7, 8) .
Increased risks also apply to rare tumor types e.g. cancer of the small intestine, upper urinary tract cancer, gastric cancer, brain tumors, and sebaceous skin tumors. HNPCC is caused by germline mismatch repair (MMR) gene mutations most commonly affecting MLH1, MSH2, and MSH6 with more than 500 mutations in these genes identified worldwide (9) . The underlying genetic defect causes widespread microsatellite instability (MSI) in the tumors and this phenomenon is, together with an immunohistochemical loss of expression of the affected MMR protein, utilized in the diagnosis of HNPCC (10) (11) (12) . 4 Approximately 2% of ovarian cancer has been estimated to be caused by HNPCC and these tumors represent epithelial ovarian cancers that often develop at younger age, mean 41-49 years, compared to the sporadic cases with a mean age of 60-65 years (13) (14) (15) . In order to determine the frequency of defective MMR and the contribution of the various MMR genes in the development of ovarian at young age, we characterized the expression of MLH1, PMS2, MSH2, and MSH6 in a population-based series of 98 women who developed epithelial ovarian cancer at young (≤40 years) age.
Patients and Methods

Collection of materials
Ethical approval for the study was granted by the ethics committee at Lund University. The regional part of the National Swedish Cancer Registry was used to identify all ovarian malignancies diagnosed ≤40 years of age during the time period January 1970 through Second primary malignancies among the 98 women were identified through the National Cancer Registry and family histories of cancer were collected from clinical files and the cancer cases were confirmed in the Cancer Registry.
Immunohistochemistry
The MMR proteins MLH1, MSH2, MSH6 and PMS2 were immunohistochemically examined on fresh 4-µm sections from paraffin-embedded tumor blocks. The sections were mounted on DAKO ChemMate Capillary Gap Microscope Slides (DAKO A/S Glostrup, Denmark), dried at room temperature overnight, followed by 1-2 hour incubation at 60°C. Xylol was used for deparaffinisation and for rehydration the slides were run through a series of descending alcohol concentrations. Antigen retrieval was achieved by microwave treatment in 10 mM Tris, 1mM EDTA, pH 9, at 800 W for 8 minutes, followed by 15 minutes at 300 W. 
Microsatellite instability (MSI)
DNA was extracted from three 10-µm sections of paraffin-embedded tissue though incubation in EDTA-Tris-buffer with Proteinase K at 65˚C for at least 2 hours, followed by boiling, centrifugation and removal of the aqueous phase, which was stored at 4˚C. The microsatellite status was determined using the markers BAT25, BAT26, BAT34C4 and BAT40, all of which are among the markers recommended by the National Cancer Institute (NCI) (16) . The 
Results
Among the ovarian cancers that developed in this population-based series 58/98 (59%) were early stage (table 1) . Tumor histology was serous in 45% of the tumors, followed by mucinous in 27%, and endometrioid in 16% (table 1) 
Discussion
Although tumor development at young age is a hallmark of heredity, differences in the contribution of heredity and the age of onset seem to apply for different tumor types as well as for the different hereditary syndromes. In colorectal cancer, 10-20% of the tumors that develop before age 45 are estimated to be caused by HNPCC and an additional fraction is probably caused by other types of heredity (17) . Studies that have assessed the contribution of the breast-ovarian cancer syndrome to the development of breast cancer before age 45 have concluded that 5-10% of the cases are caused by mutations in BRCA1 and BRCA2 (18) (19) (20) .
Hereditary ovarian cancer has primarily been associated with BRCA mutations with 20-40% life-time risk of ovarian cancer for mutation carriers and tumor development at a mean age of 50-55 years (21, 22) . Assessment of BRCA mutations among women diagnosed before age 30 have, however, not identified BRCA gene mutations, but rather suggested involvement of HNPCC in young females with invasive epithelial ovarian cancer (23) . HNPCC has been estimated to contribute to about 2% of ovarian cancer, thus to an equal overall proportion as 8 to colorectal cancer and endometrial cancer, but is associated with early tumor development with most affected individuals being in their forties (13) (14) (15) 23) .
Overall, a MSI-high phenotype has been identified in 18% of ovarian cancer (16, (24) (25) (26) (27) (28) (29) (30) . However, only occasional tumors are associated with HNPCC, and about half of the tumors have shown somatic hypermethylation of the MLH1 promotor, which suggests that other genetic causes underly the remaining MSI tumors (24) . We identified MMR-defects in 6 of the 98 tumors studied. Only one case (patient 37) had no family history of cancer and developed a clear cell cancer with concomitant loss of MLH1/PMS2, which is likely to indicate somatic MMR gene inactivation. This is supported also by the identification of a BRAF V599E mutation in this tumor (data not shown). The remaining tumors are likely to be associated with HNPCC based on loss of MSH2, family history of cancer or identification of a diseasecausing germline mutation (table 2). Only 2 women (both of whom had tumors with retained MMR expression) developed metachronous breast cancer at ages 43 and 58 years, respectively, which indicates that the breast-ovarian cancer syndrome has a minor, if any, importance for ovarian cancer development at young age. This is also in line with the findings by Stratton et al. who did not identify any BRCA cases among 101 individuals with earlyonset ovarian cancer, whereas HNPCC-causing mutations were identified in 2% of the women (31) . This estimated may represent an underestimate since large intragenic deletions and mutations in MSH6 were not accounted for. In our series, three tumors showed loss of MSH6 only, which may suggest an underlying mutation in this gene. MSH6 has been shown to confer a lower risk of colorectal cancer and a particularly high risk of endometrial cancer (32) .
The identification of HNPCC cases among women with ovarian cancer at young age implicates that the family history of cancer should include also other types of HNPCC-related cancers, most commonly colorectal cancer and endometrial, which is important since prophylactic measures and control programmes for these tumor types have proven effective (5, 33) . However, the vast majority of ovarian cancers, also at young age, develops because of unknown mechanisms and can not be linked to the currently identified genetic syndromes.
Serous and seropapillary tumors constitute about 50% of ovarian cancer, whereas endometrioid, clear cell, and mucinous tumors each constitute about 10% of the tumors (34) . In our study mucinous and endometrioid tumors were overrepresented and occurred in 27% and 16%, respectively (table 1), which is in line with the high proportion of mucinous tumors identified by Stratton et al. (31) . Among the MMR defective ovarian cancers identified herein, 3 were endometrioid, 2 were clear cell cancers, and one was a mucinous ovarian cancer. Both endometrial cancers and clear cell cancers represent rare subtypes that show MMR defects in a high (14-37%) fraction of the tumors and these histopathological types have also been linked to HNPCC (14, (26) (27) (28) (29) .
Conclusion
In summary, we identified a large fraction of mucinous and endometrioid cancers in this population-based cohort of young women with epithelial ovarian cancer. Defective MMR was identified in 6% of the tumors and suggests that HNPCC has a larger impact on ovarian cancer development in young women than the more frequently recognized hereditary breast and ovarian cancer syndrome. Identification of HNPCC-families is important since control programmes may effectively prevent additional cases of the more common colorectal and endometrial cancers. However, even among young women 9 out of 10 tumors develop because of unknown causes, which suggests that other mechanisms need to be studied to reveal if the high frequency of mucinous and endometrioid ovarian cancers may reflect distinct tumorigenic pathways.
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